Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
741 to 760 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Frequency of Pathogenic Germline Mutations in Early and Late Onset Familial Breast Cancer Patients Using Multi-Gene Panel Sequencing: An Egyptian Study. | Genes (Basel) | 2022 | 36672847 | PubTator, text mining | PubMed |
| Expressional and functional characteristics of checkpoint kinase 1 as a prognostic biomarker in hepatocellular carcinoma. | Transl Cancer Res | 2022 | 36644193 | PubTator, text mining | PubMed |
| Sociodemographic, Clinical, and Variation Outcomes for Breast Cancer and Breast Cancer-Related Mutations in a Ten-Year Cohort From Neiva, Huila, Colombia. | Cureus | 2022 | 36620844 | PubTator, text mining | PubMed |
| Association of TP53 clonal hematopoiesis with indeterminate potential with the development of myeloid neoplasms after rucaparib treatment. | Ann Transl Med | 2022 | 36618808 | PubTator, text mining | PubMed |
| Prognostic and Immunological Implications of FAM72A in Pan-Cancer and Functional Validations. | Int J Mol Sci | 2022 | 36613817 | PubTator, text mining | PubMed |
| The Adaptability of Chromosomal Instability in Cancer Therapy and Resistance. | Int J Mol Sci | 2022 | 36613695 | PubTator, text mining | PubMed |
| Differentially Expressed Genes and Signaling Pathways Potentially Involved in Primary Resistance to Chemo-Immunotherapy in Advanced-Stage Gastric Cancer Patients. | Int J Mol Sci | 2022 | 36613445 | PubTator, text mining | PubMed |
| Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can! | Cancers (Basel) | 2022 | 36612041 | PubTator, text mining | PubMed |
| Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer. | Front Oncol | 2022 | 36591485 | PubTator, text mining | PubMed |
| Genomic features of mediastinal germ cell tumors: a narrative review. | Mediastinum | 2022 | 36582975 | PubTator, text mining | PubMed |
| Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer. | NPJ Precis Oncol | 2022 | 36581696 | PubTator, text mining | PubMed |
| Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant. | Cold Spring Harb Mol Case Stud | 2022 | 36577523 | PubTator, text mining | PubMed |
| PROpel trial: Are PARP inhibitors ready to become the first-line treatment for mCRPC? | Indian J Urol | 2022 | 36568449 | PubTator, text mining | PubMed |
| Implementation of multigene panel testing for breast and ovarian cancer in South Africa: A step towards excellence in oncology for the public sector. | Front Oncol | 2022 | 36568162 | PubTator, text mining | PubMed |
| BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents. | Medicina (Kaunas) | 2022 | 36557020 | PubTator, text mining | PubMed |
| Real-World Results from Combined Screening for Monogenic Genomic Health Risks and Reproductive Risks in 300 Adults. | J Pers Med | 2022 | 36556183 | PubTator, text mining | PubMed |
| Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients. | Int J Mol Sci | 2022 | 36555431 | PubTator, text mining | PubMed |
| Pathologic Findings at Risk Reducing Surgery in BRCA and Non-BRCA Mutation Carriers: A Single-Center Experience. | Diagnostics (Basel) | 2022 | 36553061 | PubTator, text mining | PubMed |
| Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. | Biomedicines | 2022 | 36551764 | PubTator, text mining | PubMed |
| Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets. | Cancers (Basel) | 2022 | 36551731 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=38